TY - JOUR
T1 - A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-α in patients with metastatic renal cell carcinoma
AU - Ryan, Christopher W.
AU - Vogelzang, Nicholas J.
AU - Stadler, Walter M.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2002/5/15
Y1 - 2002/5/15
N2 - BACKGROUND. The objective of this study was to determine the response rate and toxicity of gemcitabine and continuous-infusion 5-fluorouracil (5-FU) in combination with subcutaneous interleukin-2 (IL2) and interferon-α (IFNA) in patients with metastatic renal cell carcinoma. METHODS. Forty-one patients were treated with gemcitabine 600 mg/m2 on Days 1, 8, and 15 and continuous-infusion 5-FU on Days 1-21. The dose of 5-FU was 200 mg/m2 per day for the initial 8 patients but was reduced to 150 mg/m2 per day for all remaining patients due to toxicity. Starting on Day 15, IL2 and IFNA were administered for 4 weeks. IL2 was administered at a dose of 11 x 106 IU subcutaneously (sc) 4 days per week and IFNA was administered at a dose of 10.0 x 106 IU sc 2 days per week. RESULTS. Of 41 patients enrolled in the study, there was 1 complete response (CR), and there were 5 partial responses (PR), for an overall response rate of 14.6% (90% confidence interval [90%CI], 6.6-26.9%). The median time to disease progression was 6.6 months (90%CI, 3.9-7.5 months), and the median overall survival was 20.6 months (90%CI, 9.6-23.3 months). Toxicity was moderate to severe, with fatigue, fever, anorexia, or nausea experienced by 75-90% of patients. Mucositis and neutropenia, likely due to the gemcitabine and 5-FU, were experienced by a majority of patients. CONCLUSIONS. The addition of gemcitabine and 5-FU to subcutaneous IL2 and IFNA results in a similar response rate to what was observed in previous studies of IL2-based therapy. The toxicity of this four-drug combination is significant, and the regimen is not recommended for further development.
AB - BACKGROUND. The objective of this study was to determine the response rate and toxicity of gemcitabine and continuous-infusion 5-fluorouracil (5-FU) in combination with subcutaneous interleukin-2 (IL2) and interferon-α (IFNA) in patients with metastatic renal cell carcinoma. METHODS. Forty-one patients were treated with gemcitabine 600 mg/m2 on Days 1, 8, and 15 and continuous-infusion 5-FU on Days 1-21. The dose of 5-FU was 200 mg/m2 per day for the initial 8 patients but was reduced to 150 mg/m2 per day for all remaining patients due to toxicity. Starting on Day 15, IL2 and IFNA were administered for 4 weeks. IL2 was administered at a dose of 11 x 106 IU subcutaneously (sc) 4 days per week and IFNA was administered at a dose of 10.0 x 106 IU sc 2 days per week. RESULTS. Of 41 patients enrolled in the study, there was 1 complete response (CR), and there were 5 partial responses (PR), for an overall response rate of 14.6% (90% confidence interval [90%CI], 6.6-26.9%). The median time to disease progression was 6.6 months (90%CI, 3.9-7.5 months), and the median overall survival was 20.6 months (90%CI, 9.6-23.3 months). Toxicity was moderate to severe, with fatigue, fever, anorexia, or nausea experienced by 75-90% of patients. Mucositis and neutropenia, likely due to the gemcitabine and 5-FU, were experienced by a majority of patients. CONCLUSIONS. The addition of gemcitabine and 5-FU to subcutaneous IL2 and IFNA results in a similar response rate to what was observed in previous studies of IL2-based therapy. The toxicity of this four-drug combination is significant, and the regimen is not recommended for further development.
KW - 5-Fluorouracil
KW - Chemotherapy
KW - Gemcitabine
KW - Immunotherapy
KW - Interferon-α
KW - Interleukin-2
KW - Renal carcinoma
UR - http://www.scopus.com/inward/record.url?scp=0037093818&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037093818&partnerID=8YFLogxK
U2 - 10.1002/cncr.10528
DO - 10.1002/cncr.10528
M3 - Article
C2 - 12173327
AN - SCOPUS:0037093818
SN - 0008-543X
VL - 94
SP - 2602
EP - 2609
JO - Cancer
JF - Cancer
IS - 10
ER -